Seismic Pharmaceuticals Commences Global Phase 3 Trial of Istaroxime in Patients With Cardiogenic Shock

Summary

Seismic Pharmaceuticals commenced a global Phase 3 trial called Rescue HF CS evaluating istaroxime in approximately 600 patients with cardiogenic shock across the United States, Europe, and South America, building on four completed Phase 2 trials.